» Articles » PMID: 14722463

Conservative Treatment of Meibomian Gland Dysfunction

Overview
Specialty Ophthalmology
Date 2004 Jan 15
PMID 14722463
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the effectiveness of lid hygiene and preservative-free artificial tears for the treatment of meibomian gland dysfunction (MGD) during a 6-week period.

Methods: Suitable patients with MGD were educated about their disease and instructed to begin a regimen of lid hygiene, which included the application of a heated saline solution and the use of nonpreserved artificial tears. Baseline measurements obtained at the time of enrollment included basic tear secretion test, tear breakup time, a questionnaire grading MGD symptoms (i.e., burning, irritation, itching, sharp pains, foreign body sensation, and hazy vision), and lid margin slitlamp photographs. All measurements except for basic tear secretion were repeated at the 6-week follow-up visit. Photographs were unlabeled, and two cornea specialists graded them in a masked fashion for the presence of lid erythema, irregularity, thickness, meibomian gland capping, and telangiectasis.

Results: Thirty-seven patients with a clinical diagnosis of MGD were enrolled, and 26 patients (70%) completed the study. Initial measurement of basic tear secretion averaged 17 mm and was more than 10 mm in 81% of eyes. The tear breakup time was prolonged by an average of 3.4 seconds; in 30% of cases, it was normalized to 10 seconds or more. Symptoms improved in 88% of cases; among those, symptoms were graded mild or less in 83%, and none in 39%. Photographs before and after treatment were not significantly different.

Conclusions: In this noncontrolled case-cohort study of selected patients with MGD, lid hygiene and preservative-free artificial tears significantly improved tear breakup time and relieved symptoms of the condition.

Citing Articles

Efficacy of 1% Povidone-Iodine in the Treatment of Anterior Blepharitis-Randomized Single-Center Controlled Trial.

Assayag E, Abulafia A, Teren D, Gelman E, Givoni H, Zadok D J Clin Med. 2024; 13(23).

PMID: 39685686 PMC: 11642136. DOI: 10.3390/jcm13237227.


Treatment of Meibomian Gland Dysfunction by Classical Eyelid Hygiene Measures With and Without Additional Lipid Substitution for Tear Film Stabilization.

Weinstein I, Kelava A, Dausch D, Seitz B Eye Contact Lens. 2024; 51(3):e123-e128.

PMID: 39661458 PMC: 11850009. DOI: 10.1097/ICL.0000000000001155.


Oral Azithromycin versus Oral Doxycycline in the Treatment of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis.

Bukhari Z, Alsudais A, Bshnaq A, Alshabri M, Alqurashi A, Alghamdi A Clin Ophthalmol. 2024; 18:3353-3363.

PMID: 39600615 PMC: 11588669. DOI: 10.2147/OPTH.S480719.


Is Meibomian Gland Dysfunction One Disease? Heterogeneity Among Phenotypes.

Kim C, Locatelli E, Prislovsky A, Cabrera K, Gary A, Mandal N Cornea. 2024; 43(11):1410-1417.

PMID: 38563551 PMC: 11442144. DOI: 10.1097/ICO.0000000000003542.


Meibomian Gland Dysfunction Clinical Practice Guidelines.

Amano S, Shimazaki J, Yokoi N, Hori Y, Arita R Jpn J Ophthalmol. 2023; 67(4):448-539.

PMID: 37351738 DOI: 10.1007/s10384-023-00995-8.